Cancer Biology & Medicine最新文献_第9页

The role of intestinal flora on tumorigenesis, progression, and the efficacy of PD-1/PD-L1 antibodies in colorectal cancer. 肠道菌群对结肠直肠癌的肿瘤发生、发展和 PD-1/PD-L1 抗体疗效的作用。

IF 5.5 2区医学

Cancer Biology & Medicine Pub Date : 2023-12-23 DOI: 10.20892/j.issn.2095-3941.2023.0376

Sen Wang, Benling Xu, Yangyang Zhang, Guangyu Chen, Peng Zhao, Quanli Gao, Long Yuan

{"title":"The role of intestinal flora on tumorigenesis, progression, and the efficacy of PD-1/PD-L1 antibodies in colorectal cancer.","authors":"Sen Wang, Benling Xu, Yangyang Zhang, Guangyu Chen, Peng Zhao, Quanli Gao, Long Yuan","doi":"10.20892/j.issn.2095-3941.2023.0376","DOIUrl":"10.20892/j.issn.2095-3941.2023.0376","url":null,"abstract":"Intestinal flora affects the maturation of the host immune system, serves as a biomarker and efficacy predictor in the immunotherapy of several cancers, and has an important role in the development of colorectal cancer (CRC). Anti-PD-1/PD-L1 antibodies have shown satisfactory results in MSI-H/dMMR CRC but performed poorly in patients with MSS/pMMR CRC. In recent years an increasing number of studies have shown that intestinal flora has an important impact on anti-PD-1/PD-L1 antibody efficacy in CRC patients. Preclinical and clinical evidence have suggested that anti-PD-1/PD-L1 antibody efficacy can be improved by altering the composition of the intestinal flora in CRC. Herein, we summarize the studies related to the influence of intestinal flora on anti-PD-1/PD-L1 antibody efficacy in CRC and discuss the potential underlying mechanism(s). We have focused on the impact of the intestinal flora on the efficacy and safety of anti-PD-1/PD-L1 antibodies in CRC and how to better utilize the intestinal flora as an adjuvant to improve the efficacy of anti-PD-1/PD-L1 antibodies. In addition, we have provided a basis for the potential of the intestinal flora as a new treatment modality and indicator for determining patient prognosis.","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2023-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10875280/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139041028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bile acids, gut microbiota, and therapeutic insights in hepatocellular carcinoma. 胆汁酸、肠道微生物群和肝细胞癌的治疗见解。

IF 5.5 2区医学

Cancer Biology & Medicine Pub Date : 2023-12-23 DOI: 10.20892/j.issn.2095-3941.2023.0394

Yang Song, Harry Ch Lau, Xiang Zhang, Jun Yu

{"title":"Bile acids, gut microbiota, and therapeutic insights in hepatocellular carcinoma.","authors":"Yang Song, Harry Ch Lau, Xiang Zhang, Jun Yu","doi":"10.20892/j.issn.2095-3941.2023.0394","DOIUrl":"10.20892/j.issn.2095-3941.2023.0394","url":null,"abstract":"Hepatocellular carcinoma (HCC) is a prevalent and aggressive liver malignancy. The interplay between bile acids (BAs) and the gut microbiota has emerged as a critical factor in HCC development and progression. Under normal conditions, BA metabolism is tightly regulated through a bidirectional interplay between gut microorganisms and BAs. The gut microbiota plays a critical role in BA metabolism, and BAs are endogenous signaling molecules that help maintain liver and intestinal homeostasis. Of note, dysbiotic changes in the gut microbiota during pathogenesis and cancer development can disrupt BA homeostasis, thereby leading to liver inflammation and fibrosis, and ultimately contributing to HCC development. Therefore, understanding the intricate interplay between BAs and the gut microbiota is crucial for elucidating the mechanisms underlying hepatocarcinogenesis. In this review, we comprehensively explore the roles and functions of BA metabolism, with a focus on the interactions between BAs and gut microorganisms in HCC. Additionally, therapeutic strategies targeting BA metabolism and the gut microbiota are discussed, including the use of BA agonists/antagonists, probiotic/prebiotic and dietary interventions, fecal microbiota transplantation, and engineered bacteria. In summary, understanding the complex BA-microbiota crosstalk can provide valuable insights into HCC development and facilitate the development of innovative therapeutic approaches for liver malignancy.","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2023-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10884537/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139041025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From dichotomy to diversity: deciphering the multifaceted roles of tumor-associated macrophages in cancer progression and therapy. 从二分法到多样性：解读肿瘤相关巨噬细胞在癌症进展和治疗中的多方面作用。

IF 5.5 2区医学

Cancer Biology & Medicine Pub Date : 2023-12-14 DOI: 10.20892/j.issn.2095-3941.2023.0370

Xiumei Wang, Jun Chen, Guangshuai Jia

引用次数: 0

DNA methylation profiles in cancer: functions, therapy, and beyond. 癌症中的 DNA 甲基化图谱：功能、治疗及其他。

IF 5.5 2区医学

Cancer Biology & Medicine Pub Date : 2023-12-07 DOI: 10.20892/j.issn.2095-3941.2023.0403

Jinrong Zhu, Yongjie Yang, Li Li, Jiuren Tang, Rongxin Zhang

引用次数: 0

Large-scale loss-of-function perturbations reveal a comprehensive epigenetic regulatory network in breast cancer. 大规模功能缺失扰动揭示了乳腺癌的综合表观遗传调控网络。

IF 5.5 2区医学

Cancer Biology & Medicine Pub Date : 2023-12-07 DOI: 10.20892/j.issn.2095-3941.2023.0276

Yumei Wang, Haiyan Wang, Wei Shao, Yuhui Chen, Yu Gui, Chao Hu, Xiaohong Yi, Lijun Huang, Shasha Li, Dong Wang

{"title":"Large-scale loss-of-function perturbations reveal a comprehensive epigenetic regulatory network in breast cancer.","authors":"Yumei Wang, Haiyan Wang, Wei Shao, Yuhui Chen, Yu Gui, Chao Hu, Xiaohong Yi, Lijun Huang, Shasha Li, Dong Wang","doi":"10.20892/j.issn.2095-3941.2023.0276","DOIUrl":"10.20892/j.issn.2095-3941.2023.0276","url":null,"abstract":"Objective: Epigenetic abnormalities have a critical role in breast cancer by regulating gene expression; however, the intricate interrelationships and key roles of approximately 400 epigenetic regulators in breast cancer remain elusive. It is important to decipher the comprehensive epigenetic regulatory network in breast cancer cells to identify master epigenetic regulators and potential therapeutic targets.Methods: We employed high-throughput sequencing-based high-throughput screening (HTS2) to effectively detect changes in the expression of 2,986 genes following the knockdown of 400 epigenetic regulators. Then, bioinformatics analysis tools were used for the resulting gene expression signatures to investigate the epigenetic regulations in breast cancer.Results: Utilizing these gene expression signatures, we classified the epigenetic regulators into five distinct clusters, each characterized by specific functions. We discovered functional similarities between BAZ2B and SETMAR, as well as CLOCK and CBX3. Moreover, we observed that CLOCK functions in a manner opposite to that of HDAC8 in downstream gene regulation. Notably, we constructed an epigenetic regulatory network based on the gene expression signatures, which revealed 8 distinct modules and identified 10 master epigenetic regulators in breast cancer.Conclusions: Our work deciphered the extensive regulation among hundreds of epigenetic regulators. The identification of 10 master epigenetic regulators offers promising therapeutic targets for breast cancer treatment.","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2023-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10875281/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138814094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Peptide drugs: a new direction in cancer immunotherapy. 多肽药物：癌症免疫疗法的新方向。

IF 5.6 2区医学

Cancer Biology & Medicine Pub Date : 2023-12-07 DOI: 10.20892/j.issn.2095-3941.2023.0297

Xinghua Sui, Xiaoshuang Niu, Xiuman Zhou, Yanfeng Gao

引用次数: 0

Improving the value of molecular testing: current status and opportunities in colorectal cancer precision medicine. 提高分子检测的价值:结直肠癌精准医学的现状与机遇。

IF 5.5 2区医学

Cancer Biology & Medicine Pub Date : 2023-11-30 DOI: 10.20892/j.issn.2095-3941.2023.0293

Haiyun Li, Linwei Guo, Chenchen Wang, Xin Hu, Ye Xu

引用次数: 0

Deep insight into the B-cell associated tertiary lymphoid structure and tumor immunotherapy. 深入了解b细胞相关的三级淋巴结构和肿瘤免疫治疗。

IF 5.5 2区医学

Cancer Biology & Medicine Pub Date : 2023-11-30 DOI: 10.20892/j.issn.2095-3941.2023.0308

Jilong Yang, Jin Xu, Haotian Liu, Wanyi Xiao, Gengpu Zhang

引用次数: 0

The outpost against cancer: universal cancer only markers. 对抗癌症的前哨:通用的癌症标记。

IF 5.5 2区医学

Cancer Biology & Medicine Pub Date : 2023-11-28 DOI: 10.20892/j.issn.2095-3941.2023.0313

Chengchen Qian, Xiaolong Zou, Wei Li, Yinshan Li, Wenqiang Yu

{"title":"The outpost against cancer: universal cancer only markers.","authors":"Chengchen Qian, Xiaolong Zou, Wei Li, Yinshan Li, Wenqiang Yu","doi":"10.20892/j.issn.2095-3941.2023.0313","DOIUrl":"10.20892/j.issn.2095-3941.2023.0313","url":null,"abstract":"Cancer is the leading cause of death worldwide. Early detection of cancer can lower the mortality of all types of cancer; however, effective early-detection biomarkers are lacking for most types of cancers. DNA methylation has always been a major target of interest because DNA methylation usually occurs before other detectable genetic changes. While investigating the common features of cancer using a novel guide positioning sequencing for DNA methylation, a series of universal cancer only markers (UCOMs) have emerged as strong candidates for effective and accurate early detection of cancer. While the clinical value of current cancer biomarkers is diminished by low sensitivity and/or low specificity, the unique characteristics of UCOMs ensure clinically meaningful results. Validation of the clinical potential of UCOMs in lung, cervical, endometrial, and urothelial cancers further supports the application of UCOMs in multiple cancer types and various clinical scenarios. In fact, the applications of UCOMs are currently under active investigation with further evaluation in the early detection of cancer, auxiliary diagnosis, treatment efficacy, and recurrence monitoring. The molecular mechanisms by which UCOMs detect cancers are the next important topics to be investigated. The application of UCOMs in real-world scenarios also requires implementation and refinement.","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2023-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690883/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138453225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging trends in clinical cancer genomic research. 临床癌症基因组研究的新趋势。

IF 5.5 2区医学

Cancer Biology & Medicine Pub Date : 2023-11-28 DOI: 10.20892/j.issn.2095-3941.2023.0383

Yingyan Yu

引用次数: 0